A practical reference on Melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-04 and is reviewed periodically as new material appears.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Fabrication and coating of nanodevices and medical implants to increase biocompatibility. Emulsifiers in food industry and personal care products. Hydrophobins' high stability can be very useful in the coating of surfaces of prolonged use or under harsh conditions. The easy dissociation of a class II hydrophobin monolayer might be desirable and this can easily be achieved by the use of detergents and alcohols. The use of hydrophobins in protein purification, drug delivery and cell attachment has been reported. For more about the potential biotechnological applications of hydrophobins see Hektor & Scholtmeijer (2005) and Cox & Hooley (2009).
==== Safety concerns ==== The European Commission's Scientific Committee on Consumer Safety (SCCS) issued an official opinion in 2021, where it considered whether the nanomaterial hydroxyapatite was safe when used in leave-on and rinse-off dermal and oral cosmetic products, taking into account reasonably foreseeable exposure conditions. It stated:
=== 2000 === 13 March The Secret Life of the Crash Test Dummy, about the biomechanics of car crashes; a typical crash test dummy cost around £100,000, with about three hundred individual parts, that had to be included by safety law, and new cars could not be sold until the dummy had tested it sufficiently; the Volvo 300 1980s television advert; Lt-Col Wayne Mattson of the USAF and a strange crash in New Mexico, one hundred miles north of the Trinity (nuclear test), and near White Sands Missile Range, where German V-2 missiles were being tested, which were conveniently blamed by the USAF on anthropomorphic dummies; John Melvin (engineer) and the legacy of USAF biophysicist and doctor Colonel John Stapp, who mostly invented aviation safety testing; John Stapp conducted gruesome horrific deceleration tests on himself; Alderson had made artificial limbs for injured USAF World War II pilots, so made a full artificial proto-human; John Stapp tested his dummies in vehicles; Clarence Ditlow and the Center for Auto Safety; in 1966 it became legal in the US for new cars to have been tested by dummies; mathematical models of injury were needed, to translate the acquired crash data into possible effects on the human body, worked out by mechanical engineer Walter Pilkey of the University of Virginia; Scottish orthopaedic surgeon Angus Wallace and impact speed on bone tensile strength; in 1976 the Hybrid III dummy was designed, the automotive industry standard design; David Abbott, advertising executive; the data for designing the crash test dummy, Hybrid III, was mostly derived from data procured for human male occupants - and typical (fiftieth percentile) males, not female, and females had much different bodies; child dummies were essentially smaller adult male dummies, which was not biologically true; new dummies were developed at the National Transportation Biomechanics Research Center. Narrated by Andrew Lincoln, produced by Cathy Rogers, directed by Peter Webber, made by RDF Television. Shown on Wednesday 17 January 2001 on The Nature of Things in Canada 20 March Rise and Fall of GM Food, about genetically modified food; Belgian geneticist Marc Van Montagu, of the University of Ghent, visits Havana in Cuba, where a new research centre opened with Carlos Borroto; protests by topless women; GM was largely first developed by Mexican geneticist Herrera Estrella, of the Centre of Investigation and Advanced Studies; Rob Fraley of Monsanto; US farmers spend $8bn dollars on herbicides and pesticides; Roger N. Beachy had a breakthrough in 1986 at the Washington University in St. Louis, now at the Donald Danforth Plant and Science Center; Monsanto made the first insecticide-resistant plant in 1987; many African farmers cannot afford insecticides; Cyrus Ndiritu of the Kenya Agriculture Research Institute; much food harvested in Africa does not last before it reaches the consumer; in 1990 Don Grierson of the Plant Science Division of the University of Nottingham found genes of ripening; Channapatna Prakash of Tuskegee University in Alabama; aluminium toxicity of soils in tropical countries affected yield; Julian Borger of The Guardian; biologist Mae-Wan Ho of the Open University; biologist John Gatehouse of the University of Durham, and the Pusztai affair at The Rowett Institute; Helen Browning, Chairman of the Soil Association; former Vice-Chancellor of UEA, Derek Burke; former Independent environment correspondent Richard D. North, who had grown out of love with the hard-line environmental movement; European farmers grew five times more produce than they did in the 1960s, and there were twice as many trees in the UK than in the 1920s; Renée Elliott of Planet Organic; around 100m children in Third World countries suffered from Vitamin A deficiency. Directed by Martin Durkin, made by his company Kugelblitz 27 March Simply Complex, about the physicist Murray Gell-Mann; by an accident, he devised strangeness of sub-atomic particles, in his mid-20s; he predicts an omega minus particle, which was found in 1962; he predicts that the proton and neutron were made of three triplet particles, which he called quarks from Finnegans Wake and his Eightfold way (physics), also predicted by George Zweig; he worked closely with Richard Feynman at Caltech in the 1960s; on 30 October 1969 he is told that he had won the Nobel Prize for Physics; his friendship with MIT mechanical engineer Seth Lloyd; British physicist Geoffrey West; the documentary is in a biographic informal style that Horizon has since often followed. Produced by Barbara Altounyan, directed by Celia Lowenstein, made by Diverse Productions 3 April Meningitis - Search for a Cure, 3,000 people in the UK had meningitis in 1999; microbiologist Martin C. J. Maiden; one in five died from meningococcal disease; damage is caused by the endotoxin (lipopolysaccharide); a healthy survey is carried out at Burford School; Mike Levin (paediatrician) at Imperial College, and how meningitis A is a huge danger in Africa; 60% of cases in the UK are meningitis B, and many such cases are treated at St Mary's Hospital, London; Brett Giroir of the Children's Medical Center Dallas; 17-year-old Amy Mansell from Whitstable was in a coma for five weeks. Narrated by Paul Brightwell, produced by David Dugan, directed by Jeremy Llewellyn-Jones, made by Windfall Films with Nova and WGBH Boston. It was shown on Nova as Killer Disease on Campus, episode 9 of season 29, shown on 3 September 2002, and shown under the original programme title as a half-hour programme on 6 November 2003 on Catalyst on ABC in Australia 10 April The Box, about flight recorders, with ValuJet Airlines Flight 592 which crashed on 11 May 1996; voice recorders have been compulsory since the late 1960s; Dukane Seacom make emergency underwater locator beacons (ULBs); the Boeing 737, which had around 21,000 take-offs per day, was believed to have unreliable rudder control since the 1980s, as shown in the United Airlines Flight 585 crash on 3 March 1991, having had two rudder incidents in the previous two weeks, with the aircraft flipping 35 seconds after take-off and crashing all in seven seconds; the electrohydraulic servo valve in the Boeing 737 rudder control unit was thought to be sometimes temperamental; Boeing claimed that the March 1991 crash was due to a rotor or lee wave, caused by nearby mountains; the USAir Flight 427 crash on 8 September 1994, where the aircraft flipped at 6,000 ft, in 28 seconds crashing; British Airways did not rely on their Penny & Giles quick access recorders, and would consolidate this data where anomalies were checked, so the NTSB needed BA's data for their 737 aircraft; this safer BA method was introduced by the previous British European Airways (BEA) when it had to prove to the CAA that its autoland system for the Trident was safe, in the Civil Aircraft Airworthiness Data Recording Programme which since 1990 has been collected by the British Airways Safety Information System (BASIS); the 1991 crash investigation concluded after 8 years in 1999, with Boeing ordered to redesign the servo valve. 9 October Full Throttle, about the technology and psychology of motor racing; Brazilian driver Christian Fittipaldi; the Eurofighter, controlled by computers, and due to enter RAF service in 2002; Archie Neill, BAE test pilot; Stephen Olvey, motor racing medical officer; driver Mark Blundell; the Long Beach Grand Prix in Los Angeles; Steve Clark, engineer for Mercedes; Brian Lisles and Peter Gibbons of Newman Haas Racing; the edge of performance envelope; Mario Andretti, former driver: Edward Winter of Sheffield Hallam University and predicting outcomes in sport, by intuition; John Rothwell of the Institute of Neurology in London, testing reflexes, by an MRI scanner, and how the brain stores instructions; psychologist Mike Land of the University of Sussex, and the psychology of prediction, and feedforward; life expectancy of racing drivers in the 1970s was short; racing drivers had risk positive personalities, and became accustomed to risk; psychologist Tim Wheeler; Jimmy Vasser of Chip Ganassi Racing; a female violinist plays La fille aux cheveux de lin; sports psychologist Brian Hemmings; Austrian driver Alexander Wurz of Benetton Formula; RAF SEPECAT Jaguar XZ103 of 41 Squadron; engineer Pat Symonds of Benetton Racing; Simon Taylor (journalist) of Motor Sport; Graham Rood of DERA Air Systems in north Hampshire. Narrated by Stephen Rashbrook, produced by Patrick Uden, directed by Andy Robbins, made by Uden Associates 16 October Lethal Seas: the Maelstrom, about ocean whirlpools; the Gulf of Corryvreckan in Scotland, Lofoten and Saltstraumen in Norway; with Prof Tsukasa Nishimura of Tokyo University of Science and Prof Walter Munk of the Scripps Institution of Oceanography; the Firth of Lorn in west Scotland has one of the world's most dangerous whirlpools, the Royal Navy avoids it; atmospheric physicist Peter Read; mathematician David Dritschel, and the Great Red Spot vortice; the dangerous Arran Rapids on the Cordero Channel in western Canada; Burkard Baschek of the Institute of Ocean Sciences, who dropped a CTD (instrument) into the torrential river currents; Tremble Island in the notorious Slingsby Channel, where a geophone was placed; the novel A Descent into the Maelström; Bjørn Gjevik, a fluid dynamicist in the Department of Mathematics, at the University of Oslo; strong tidal currents in the Naruto Strait in Japan, and the Naruto whirlpools. Narrated by Stephen Rashbrook, produced by Robert Sproul-Cran, directed by Kim Flitcroft, made by Northlight Productions with the Discovery Channel 23 October Einstein's Biggest Blunder, about calculations of the expansion of the universe; the documentary opens with a pastiche of the Star Wars opening credits; two physicists met in 1996, with a new radical proposal for explaining the many anomalies in the expansion of the universe - Andreas Albrecht (cosmologist) of the University of California, Davis and João Magueijo of Portugal; Dave Wark of the University of Sussex, visits Bern in Switzerland; Ruth Durrer of the University of Geneva; John E. Baldwin of the University of Cambridge, and the 1887 Michelson–Morley experiment, which found that the Earth's rotational speed did not affect the speed of light in any way, alongside the Venus movement of The Planets; to account for this, Einstein made his field equations, and lambda - the cosmological constant was added by Einstein to account for how space-time would need to expand; Einstein's equations inferred that the expansion of the universe rested on inherently unstable conditions; due to the Doppler effect, background radiation from the Big Bang is now perceived as microwave radiation; Richard Ellis (astronomer) of Caltech; Einstein didn't believe in the Big Bang until a meeting with Hubble in 1932 in California; with the new theory of an expanding universe, the cosmological constant was now required, but the precise trajectory of the expansion of the universe could not be directly predicted, which led to the flatness problem; the theory of inflation was put forward by Alan Guth in the 1970s; when at St John's College, Cambridge, João Magueijo had the radical proposal that if the speed of light was higher, in the early universe, a cosmological horizon of sufficient distance would be possible, to explain the predicted conditions of the expansion of the early universe, and the cosmological constant problem; the Royal Society gave him a research fellowship to work at Imperial College; as further exploratory work was clocked up, with calculations inclya variable speed of light, the team of physicists looked at other applications for their controversial proposals, such as the flatness problem, and what happened before the Big Bang; in 1998 astrophysicist John Webb, at the University of Cambridge, worked on the theory of a variable speed of light, through investigating quasars, the most distant objects that can be seen; and by looking at supernovae, it was largely expected that any recorded data would show indications of a deceleration in the rate of expansion of the universe, but the data instead showed that the rate of expansion was - increasing, which led to the lambda-CDM model. Narrated by Scottish actor Matthew Zajac, directed by David Sington, made by Dox Productions 30 October The Science of Stress, with 42-year-old actor Angus Kennedy; endocrinologist Stafford Lightman of the University of Bristol; Vivette Glover, a perinatal psychobiological at Imperial College; Sir Cary Cooper, psychologist at the former UMIST; Carolyn M. Mazure, psychiatrist at Yale School of Medicine; Charles Nemeroff, psychiatrist at Emory University School of Medicine. Narrated by Geoffrey Palmer, directed by Michael Samuels, produced by Bridget Sneyd, made by Lion Television and the Discovery Health Channel 7 December Science of Crime - Psychopath, with psychologists Robert D. Hare and Adrian Raine, about the psychopathic traits of insincere superficial charm, on the Psychopathy Checklist. Narrated by Neil Pearson, directed by John Purdie, produced by Rosalind Arden, made by Union Pictures 14 December Science of Crime - Criminal Evidence, about the forensic psychologist 49-year-old Kathy Reichs. Produced by Geoff Deehan, directed by Roger Pyke, made by Yap Films 21 December Science of Crime - Cybercops, the Hackers on Planet Earth conference; Cult of the Dead Cow, founded by Swamp Rat, and its Back Orifice software for accessing Windows 98; the Happy99 virus; wardialing; part of the High Technology Theft Apprehension and Prosecution Program in California. Narrated by Steven Mackintosh, written by Callum Macrae, directed by Witold Starecki
Sources: en.wikipedia.org
In terms of the mechanism of action of benzodiazepines, their similarities are too great to separate them into individual categories such as anxiolytic or hypnotic. For example, a hypnotic administered in low doses produces anxiety-relieving effects, whereas a benzodiazepine marketed as an anti-anxiety drug at higher doses induces sleep. The subset of GABAA receptors that also bind benzodiazepines are referred to as benzodiazepine receptors (BzR). The GABAA receptor is a heteromer composed of five subunits, the most common ones being two αs, two βs, and one γ (α2β2γ1). For each subunit, many subtypes exist (α1–6, β1–3, and γ1–3). GABAA receptors that are made up of different combinations of subunit subtypes have different properties, different distributions in the brain, and different activities relative to pharmacological and clinical effects. Benzodiazepines bind at the interface of the α and γ subunits on the GABAA receptor. Binding also requires that alpha subunits contain a histidine amino acid residue, (i.e., α1, α2, α3, and α5 containing GABAA receptors). For this reason, benzodiazepines show no affinity for GABAA receptors containing α4 and α6 subunits with an arginine instead of a histidine residue. Once bound to the benzodiazepine receptor, the benzodiazepine ligand locks the benzodiazepine receptor into a conformation in which it has a greater affinity for the GABA neurotransmitter. This increases the frequency of the opening of the associated chloride ion channel and hyperpolarizes the membrane of the associated neuron.
At the start of 2016, experts warned the Philippines was at risk of having the Islamic State of Iraq and Syria (ISIS) set a foothold in the country. However, Duterte's predecessor, President Aquino III, dismissed the perpetrators of a March 2016 armed attack against the military as mere "mercenaries" wanting to join the ISIS. The earliest terrorist attacks in Duterte's presidency occurred in September 2016 in Davao City; November 2016 in Butig, Lanao del Sur; and in April to May 2017 in Inabanga, Bohol, where the Abu Sayyaf Group (ASG) attempted to establish a position in the Visayas. Though the military eventually quelled the sieges, the events were only a prelude to what would become Duterte's greatest challenge in combating terrorism.
In a 2024 survey by marketing research firm Ipsos, Asia–Pacific countries were significantly more optimistic than Western societies about generative AI and show higher adoption rates. Despite expressing concerns about privacy and the pace of change, 68% of Asia-Pacific respondents believed that AI was having a positive impact on the world, compared to 57% globally. According to a survey by SAS and Coleman Parkes Research, as of 2023, 83% of Chinese respondents were using the technology, exceeding both the global average of 54% and the U.S. rate of 65%. A UN report indicated that Chinese entities filed over 38,000 generative AI patents from 2014 to 2023, more than any other country. A 2024 survey by the Just So Soul social media app reported that 18% of respondents born after 2000 used generative AI "almost every day", and that over 60% of respondents like or love AI-generated content (AIGC), while less than 3% dislike or hate it. By mid-2025, companies were increasingly abandoning generative AI pilot projects as they had difficulties with integration, data quality and unmet returns, leading analysts at Gartner and The Economist to characterize the period as entering the Gartner hype cycle's "trough of disillusionment" phase. In an October 2025 survey by the Federal Reserve, one in four U.S. workers reported using generative AI at work during the previous month.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.